Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics insider plans a new stock sale. A Form 144 notice shows that Catherine Sohn intends to sell up to 26,920 shares of Maze Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,052,784.67. The shares are listed as being sold on NASDAQ, with an approximate sale date of January 7, 2026, and 48,119,444 common shares outstanding.
The filing states that the 26,920 shares were acquired on January 7, 2026 via a stock option exercise from the issuer, paid in cash. It also discloses that during the past three months, Catherine Sohn sold 2,493 Maze Therapeutics common shares on January 6, 2026 for gross proceeds of $96,269.69. By signing, the seller represents they are not aware of undisclosed material adverse information about the company.
A shareholder of MAZE has filed a Form 144 notice to sell 2,493 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ on or about 01/06/2026. The shares to be sold were acquired the same day via a stock option exercise for cash. The filing lists an aggregate market value of $96,269.69 for the planned sale, compared with 48,119,444 shares outstanding of the same class. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about MAZE’s current or prospective operations.
Maze Therapeutics, Inc. officer Harold Bernstein reported option exercises and share sales. On January 2, 2026, he exercised stock options to acquire 4,432 shares of common stock at $10.42 per share and sold 4,432 shares of common stock at a weighted average price of $40.4304 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025. On January 5, 2026, he exercised options to acquire an additional 412 shares at $10.42 and sold 412 shares at $40.00 per share. Following these transactions, he continued to hold stock options, including 337,563 option shares directly owned, which vest over time according to a set schedule.
Maze Therapeutics SVP of Finance Amy Bachrodt reported option exercises and share sales in company stock. On January 2, 2026, she exercised stock options for 204 and 4,796 shares of common stock at an exercise price of $10.42 per share. These options relate to grants that vest monthly and one award that was fully vested as of March 1, 2025.
On the same date, she sold 2,405 shares at a weighted average price of $38.6995 and 2,595 shares at a weighted average price of $39.5689, in multiple trades within stated price ranges. After these transactions, she directly held 12,965 shares of common stock and 2,377 and 2,983 stock options. All trades were executed under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Maze Therapeutics, Inc. director reports receipt of common stock through fund distribution. A Maze Therapeutics, Inc. (MAZE) director reported acquiring 1,489 shares of common stock on 11/19/2025 at a price of $0 per share, described as his pro rata share of a distribution from entities affiliated with Third Rock Ventures made for no consideration under an Exchange Act exemption. Following this transaction, he beneficially owns 31,113 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, for which he serves as trustee. This is a routine ownership reporting update rather than a new open-market purchase or sale.
Maze Therapeutics (MAZE) reported Q3 2025 results with a net loss of $30,087,000, reflecting higher R&D and G&A spending as programs advance. There was no license revenue in the quarter, versus $2,500,000 in Q3 2024.
Operating expenses rose to $32,965,000 (R&D $25,190,000; G&A $7,775,000). Interest and other income contributed $2,878,000. Year‑to‑date, the company recorded a net loss of $96,552,000, compared to net income in 2024 driven by one‑time license payments.
Liquidity strengthened significantly in 2025. Cash, cash equivalents and marketable securities totaled $383.9 million as of September 30, 2025. The company completed an IPO in February 2025 (8,750,000 shares at $16.00, net proceeds ~$127.8 million) and a September 10, 2025 private placement (4,000,002 shares at $16.25 and 5,231,090 pre‑funded warrants at $16.249, net proceeds ~$141.3 million). A $50 million revolving line was extended to June 2026. Shares outstanding were 48,119,444 as of November 3, 2025.
Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.
The press release, dated November 6, 2025, is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” limiting its treatment under certain securities law liability provisions.
Maze Therapeutics, Inc. filed a Rule 424(b)(3) prospectus covering the resale of up to 9,231,092 shares of common stock by selling stockholders. This includes 4,000,002 Initial Shares and up to 5,231,090 Warrant Shares issuable upon exercise of pre-funded warrants issued in a September 2025 private placement.
The company is not selling any securities in this prospectus and will not receive proceeds from sales by the holders. Upon any cash exercise of the pre-funded warrants (exercise price $0.001 per share), the company would receive the exercise price. The shares may be sold at market or negotiated prices through brokers, dealers, agents, or direct sales. The warrants include a 4.99% or 9.99% beneficial ownership cap. As context, shares outstanding were 48,076,885 as of September 30, 2025. Examples of registered resale amounts include Entities Affiliated with Baker Brothers 1,538,556 and Janus Henderson 1,230,769. Common stock trades on Nasdaq as MAZE.
Maze Therapeutics (MAZE): Form 4 insider activity
Affiliates of Third Rock Ventures reported a pro rata, for-no-consideration distribution of 1,600,000 shares of Maze Therapeutics common stock on November 4, 2025, noted with transaction code J and described as exempt under Rules 16a-13 and 16a-9. Following the distribution, the filing shows 4,473,958 shares beneficially owned directly and 950,800 shares beneficially owned indirectly, with relationships indicated including director and 10% owner statuses and standard beneficial ownership disclaimers among the TRV entities.
Maze Therapeutics (MAZE) reported an insider transaction by a director. On 10/23/2025, the reporting person made a gift of 28,423 shares of common stock, recorded at $0 as a no‑consideration transfer exempt under Rule 16b‑5.
Following the transaction, the filer beneficially owned 29,624 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is trustee.